4CB 1
Alternative Names: 4CB-1; Alpha 4CB-1.1; Anti-4CB1; α4CB-1.1Latest Information Update: 28 Oct 2025
At a glance
- Originator 4C Biomed
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Tumour necrosis factor ligand superfamily member 14 inhibitors
- 
          
            
              Orphan Drug Status
              NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral, Injection)
- 30 Apr 2024 4C Biomed plans a clinical trial for Cancer in third quarter of 2025
- 02 Apr 2024 Adverse events and pharmacodynamics data from a preclinical trial in Cancer released by 4C Biomed (4C Biomed pipeline, April 2024)
